Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Targeting intracelular RANKL in breast cancer

Project description

Targeting a tougher form of breast cancer

Triple-negative breast cancer is challenging to treat due to limited therapeutic options. Affecting hundreds of thousands of women each year, this aggressive form of breast cancer often returns after treatment. With this in mind, the ERC-funded IntraRANKL project aims to develop a new class of drugs that block RANKL, a protein linked to cancer growth and metastasis, through a mechanism unlike the current treatments such as denosumab. These small-molecule inhibitors could offer more precise, effective therapy for TNBC and potentially other RANKL-expressing cancers. The goal is to improve treatment outcomes and reduce relapse, bringing patients new hope.

Objective

Breast cancer is the most common malignancy among females in the western world, resulting in half a million deaths annually, mainly due to metastatic disease. Triple negative breast cancer (TNBC) accounts for 15–20% of all breast cancers (300.000 women diagnosed worldwide per year). Despite novel treatments, TNBC remains a clinical challenge due to high rate of relapse, a propensity to form visceral metastasis and its heterogeneity. There is an urgent need to identify novel targeted therapies and associated biomarkers for the treatment of the TNBC. IntraRANKL is based on the generation of innovative drugs targeting RANKL – for the treatment of TNBC, with a different mechanism of action than denosumab, the gold standard treatment against RANKL.
Small molecule inhibitors generated in IntraRANKL could plausibly be positioned as a novel targeted therapy for TNBC. The main benefits of IntraRANKL are based on the unmet need to improve the treatment of TNBC patients, and the economic burden for public health systems generated by standard non-selected and ineffective cancer treatments. Although our drugs are aimed for TNBC, they can benefit other breast cancer subtypes and tumors expressing RANKL. Moreover, if drugs against RANKL prove to be efficient, they could also clinically benefit patients suffering bone metastasis that are currently treated with denosumab and bisphosphonates. Analyses of RANKL will allow to stratify patients that might benefit from IntraRANKL inhibitors, improving the existing treatments for skeletal-related events and reducing the main complications associated with lifealtering morbidity affecting several types of prevalent cancers.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-ERC-POC - HORIZON ERC Proof of Concept Grants

See all projects funded under this funding scheme

Call for proposal

(opens in new window) ERC-2024-POC

See all projects funded under this call

Host institution

FUNDACION SECTOR PUBLICO ESTATAL CENTRO NACIONAL INVESTIGACIONES ONCOLOGICAS CARLOS III
Net EU contribution
€ 150 000,00
Address
C MELCHOR FERNANDEZ ALMAGRO 3
28029 Madrid
Spain
Region
Comunidad de Madrid Comunidad de Madrid Madrid
Activity type
Research Organisations
Links
Total cost
No data

Beneficiaries (1)